A recent study suggests that people who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who end conventional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while obese individuals can lose about a fifth of their body weight while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications need to be informed of the risk of rapid rebound weight gain when the treatment concludes," warns expert Dr. Susan Jebb.
That rate of regain implies a reversion to pre-treatment mass within about one and a half years.
Analyzing Treatments
The analysis, which reviewed dozens of studies involving thousands of patients, contrasted the results of these new drugs with conventional dieting.
Researchers emphasize that people who shed pounds through diet and exercise generally see a less rapid weight regain—approximately 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Doctors suggest the mode of action of the drugs is key to understanding the accelerated regain.
The injections imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this hormone supplement means appetite is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines recommend the jabs for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of weight regain, the treatment should be considered life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "emphasize the long-term nature of excess weight," similar to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication report a sudden resurgence of hunger.
"I experienced something that goes on and you become starving," said a patient.
This challenge is worsened if individuals have not established sustainable dietary or behavioural changes during treatment.
Growing Adoption
Recent estimates show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.
- Use is more common among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, experts caution that while these medications are potent tools for shedding pounds, they are not a magic solution and maintained weight loss likely depends on integrated behavioural support.
